Evidence map›Paper›PMID 41105522›Full record

ArticleAntimicrobial agents and chemotherapy2025

Optimizing antimicrobial susceptibility testing: cost and environmental benefits of MIC volume reduction.

Jonathan Clarhaut, Jeremy Moreau, Tom Collet, Emma Babiard, Vincent Aranzana-Climent, Sandrine Marchand, Kevin Brunet, Julien M Buyck

Abstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jonathan ClarhautUniversité de Poitiers, PHAR2, Inserm U1070, Poitiers, France.ORCID 0000-0001-6958-2668
Jeremy MoreauUniversité de Poitiers, PHAR2, Inserm U1070, Poitiers, France.
Tom ColletUniversité de Poitiers, PHAR2, Inserm U1070, Poitiers, France.
Emma BabiardUniversité de Poitiers, PHAR2, Inserm U1070, Poitiers, France.
Vincent Aranzana-ClimentUniversité de Poitiers, PHAR2, Inserm U1070, Poitiers, France.
Sandrine MarchandUniversité de Poitiers, PHAR2, Inserm U1070, Poitiers, France.ORCID 0000-0001-5279-6678
Kevin BrunetUniversité de Poitiers, PHAR2, Inserm U1070, Poitiers, France.
Julien M BuyckUniversité de Poitiers, PHAR2, Inserm U1070, Poitiers, France.ORCID 0000-0003-0299-4654

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The determination of minimum inhibitory concentrations (MICs) is essential for evaluating antimicrobial efficacy, guiding both clinical treatment decisions and drug development. The standard broth microdilution method is widely used but requires significant reagent volumes, which can be limiting when working with novel or expensive antimicrobials. This study assesses the feasibility of reducing assay volumes without compromising MIC accuracy. We compared the MIC values obtained in standard 96-well plates (100 and 200 µL) to those in 384-well plates with reduced volumes (30 and 50 µL) for a range of ATCC gram-negative and gram-positive bacteria, as well as yeast species. Our results demonstrate that, except for micafungin against yeast, MIC values obtained with reduced volumes remained within the acceptable variability ranges defined by EUCAST and CLSI. The consistency of the MIC evaluation in 30 µL final volume was then confirmed against a selection of gram-negative 30 clinical isolates. Evaporation, a potential source of bias in smaller volumes, was mitigated by conducting experiments in a water-saturated atmosphere. Furthermore, reduced assay volumes significantly lowered material costs and antimicrobial consumption. This miniaturization approach provides a cost-effective and high-throughput alternative for antimicrobial susceptibility testing, ensuring accuracy and reproducibility and is particularly advantageous in research settings where compound availability is limited or associated with high costs.

Indexed as

Anti-Bacterial AgentsAntifungal AgentsGram-Negative BacteriaGram-Positive BacteriaMicrobial Sensitivity TestsAnti-Bacterial AgentsAntifungal AgentsantimicrobialsGram-negativeGram-positiveMICminiaturizationsmall volumeyeast

Identifiers

PMID41105522
PMCPMC12691650

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.